Phathom Pharmaceuticals, Inc. PHAT Proceeds From Issuance Underwritten Public Offering
Proceeds From Issuance Underwritten Public Offering at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept phat:ProceedsFromIssuanceUnderwrittenPublicOffering.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s proceeds from issuance underwritten public offering.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s proceeds from issuance underwritten public offering?
- Phathom Pharmaceuticals, Inc. (PHAT) reported proceeds from issuance underwritten public offering of $121.97M in Q1 2026.
- What does proceeds from issuance underwritten public offering mean?
- This represents the gross cash inflows generated from the sale of equity or debt securities through an underwritten public offering. It is a primary indicator of a company's ability to access capital markets to fund research, development, or commercialization activities. High proceeds indicate strong investor confidence and provide necessary liquidity for growth.